Literature DB >> 17538896

Effects of sex, parity, and sequence variation on seroreactivity to candidate pregnancy malaria vaccine antigens.

Andrew V Oleinikov1, Eddie Rossnagle, Susan Francis, Theonest K Mutabingwa, Michal Fried, Patrick E Duffy.   

Abstract

BACKGROUND: Plasmodium falciparum-infected erythrocytes adhere to chondroitin sulfate A (CSA) to sequester in the human placenta, and pregnancy malaria (PM) is associated with the development of disease in and the death of both mother and child. A PM vaccine appears to be feasible, because women become protected as they develop antibodies against placental infected erythrocytes (IEs). Two IE surface molecules, VAR1CSA and VAR2CSA, bind CSA in vitro and are potential vaccine candidates.
METHODS: We expressed all domains of VAR1CSA and VAR2CSA as mammalian cell surface proteins, using a novel approach that allows rapid purification, immobilization, and quantification of target antigen. For serum samples from East Africa, we measured reactivity to all domains, and we examined the effects of host sex and parity, as well as the effects of parasite antigenic variation.
RESULTS: Serum samples obtained from multigravid women had a higher reactivity to all VAR2CSA domains than did those obtained from primigravid women or from men. Conversely, serum samples obtained from men had consistently higher reactivity to VAR1CSA domains than did those obtained from gravid women. Seroreactivity was strongly influenced by antigenic variation of VAR2CSA Duffy binding-like domains.
CONCLUSIONS: Women acquire antibodies to VAR2CSA over successive pregnancies, but they lose reactivity to VAR1CSA. Serum reactivity to VAR2CSA is variant specific, and future studies should examine the degree to which functional antibodies, such as binding-inhibition antibodies, are variant specific.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17538896     DOI: 10.1086/518513

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  32 in total

1.  Functional antibodies against VAR2CSA in nonpregnant populations from colombia exposed to Plasmodium falciparum and Plasmodium vivax.

Authors:  Sedami Gnidehou; Justin Doritchamou; Eliana M Arango; Ana Cabrera; Maria Isabel Arroyo; Kevin C Kain; Nicaise Tuikue Ndam; Amanda Maestre; Stephanie K Yanow
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

2.  Parity-dependent recognition of DBL1X-3X suggests an important role of the VAR2CSA high-affinity CSA-binding region in the development of the humoral response against placental malaria.

Authors:  Sébastien Dechavanne; Anand Srivastava; Stéphane Gangnard; Sofia Nunes-Silva; Célia Dechavanne; Nadine Fievet; Philippe Deloron; Arnaud Chêne; Benoît Gamain
Journal:  Infect Immun       Date:  2015-03-30       Impact factor: 3.441

3.  Identification of VAR2CSA domain-specific inhibitory antibodies of the Plasmodium falciparum erythrocyte membrane protein 1 using a novel flow cytometry assay.

Authors:  Harold Obiakor; Marion Avril; Nicholas J Macdonald; Prakash Srinivasan; Karine Reiter; Charles Anderson; Kevin L Holmes; Michal Fried; Patrick E Duffy; Joseph D Smith; David L Narum; Louis H Miller
Journal:  Clin Vaccine Immunol       Date:  2013-01-23

4.  Association of Antibodies to VAR2CSA and Merozoite Antigens with Pregnancy Outcomes in Women Living in Yaoundé, Cameroon.

Authors:  Yukie M Lloyd; Rui Fang; Naveen Bobbili; Koko Vanda; Elise Ngati; Maria J Sanchez-Quintero; Ali Salanti; John J Chen; Rose G F Leke; Diane W Taylor
Journal:  Infect Immun       Date:  2018-08-22       Impact factor: 3.441

5.  Optimizing expression of the pregnancy malaria vaccine candidate, VAR2CSA in Pichia pastoris.

Authors:  Marion Avril; Marianne J Hathaway; Megan M Cartwright; Severin O Gose; David L Narum; Joseph D Smith
Journal:  Malar J       Date:  2009-06-29       Impact factor: 2.979

6.  Towards the rational design of a candidate vaccine against pregnancy associated malaria: conserved sequences of the DBL6epsilon domain of VAR2CSA.

Authors:  Cyril Badaut; Gwladys Bertin; Tatiana Rustico; Nadine Fievet; Achille Massougbodji; Alioune Gaye; Philippe Deloron
Journal:  PLoS One       Date:  2010-06-23       Impact factor: 3.240

7.  Antibodies to Escherichia coli-expressed C-terminal domains of Plasmodium falciparum variant surface antigen 2-chondroitin sulfate A (VAR2CSA) inhibit binding of CSA-adherent parasites to placental tissue.

Authors:  Tracy Saveria; Andrew V Oleinikov; Kathryn Wiliamson; Richa Chaturvedi; Joe Lograsso; Gladys J Keitany; Michal Fried; Patrick Duffy
Journal:  Infect Immun       Date:  2013-01-14       Impact factor: 3.441

8.  Multilaboratory approach to preclinical evaluation of vaccine immunogens for placental malaria.

Authors:  Michal Fried; Marion Avril; Richa Chaturvedi; Pablo Fernandez; Joseph Lograsso; David Narum; Morten A Nielsen; Andrew V Oleinikov; Mafalda Resende; Ali Salanti; Tracy Saveria; Kathryn Williamson; Alassane Dicko; Artur Scherf; Joseph D Smith; Thor G Theander; Patrick E Duffy
Journal:  Infect Immun       Date:  2012-12-03       Impact factor: 3.441

9.  High throughput functional assays of the variant antigen PfEMP1 reveal a single domain in the 3D7 Plasmodium falciparum genome that binds ICAM1 with high affinity and is targeted by naturally acquired neutralizing antibodies.

Authors:  Andrew V Oleinikov; Emily Amos; Isaac Tyler Frye; Eddie Rossnagle; Theonest K Mutabingwa; Michal Fried; Patrick E Duffy
Journal:  PLoS Pathog       Date:  2009-04-17       Impact factor: 6.823

10.  Differential recognition of P. falciparum VAR2CSA domains by naturally acquired antibodies in pregnant women from a malaria endemic area.

Authors:  Kim J M Brolin; Kristina E M Persson; Mats Wahlgren; Stephen J Rogerson; Qijun Chen
Journal:  PLoS One       Date:  2010-02-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.